Information Library
Results for: Get to market faster - Phase II/III
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
Quintiles Reaches New Milestone in Social Health
Press Release — March 28, 2011 – Quintiles announced that its online social community at www.MediGuard.org has reached 2.5 million members in just three years.
-
Podcast: MediGuard's Membership Milestone
Hear from the Experts — March 25, 2011
Hugo Stephenson, President of MediGuard, dicusses the 2.5 million member milestone. -
Exclusive Report From Scientific American
Hear from the Experts — November 9, 2010
In-depth insights on every angle of the changing health landscape - brought to you by Quintiles Get the report today. -
Oncology Drug Development and Value-Based Medicine
White Paper — November 5, 2010
This report demonstrates the need to converge clinical and commercial imperatives earlier within the drug development process to meet a future demand for value-based medical practices. -
Biomarkers as an Approach to Improving Productivity in Oncology Drug Development
Presentation — August 19, 2010
Richard Gaynor, MD of Eli Lilly presents Biomarkers as an Approach to Improving Productivity in Oncology Drug Development -
FDA Requirements for Clinical Studies in Pediatric Patients
White Paper — April 1, 2010
FDA Requirements for Clinical Studies in Pediatric Patients FDA rules around pediatric drug trials have been tightening, to ensure more targeted data on drug efficacy -
Regulations for Clinical Studies in Pediatric Patients in the European Union
White Paper — March 10, 2010
After the United States issued pediatric drug study requirements, the European Union (EU) passed a regulation that created major changes to clinical studies for pediatric -
New FDA Guidance on Antidiabetic Therapies
White Paper — December 11, 2009
Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program. -
Chasing Influenza
White Paper — November 30, 2009
The rise in influenza strains like H1N1 — and the demand for new vaccines — signals a new era in vaccines. Learn how flu vaccines have evolved and where they’re headed. -
Early Phase Optimization Strategies
Media Coverage — November 18, 2009
As payers balk at rising drug prices and patent expirations threaten the industry’s revenue streams, pharmaceutical companies worldwide are looking for ways to cut costs associated with drug development and, simultaneously, speed the process up.
